News
Daewoo Pharm and SCAI Therapeutics, joint research contract for eye drop formulation for macular degeneration treatment.
Author
SCAI Therapeutics
Date
2022-04-17 22:50
Views
650
Daewoo Pharm Co., Ltd. announced on the 17th that it has signed a technology transfer/joint research contract with SCAI Therapeutics on the 16th for macular degeneration eye drops.
Through this contract, SCAI Therapeutics will transfer the technology of SCAI-003, which is being developed as an eye drop for macular degeneration treatment using the anticancer drug Sunitinib, to Daewoo Pharm, and Daewoo Pharm will grant joint clinical trials and exclusive sales rights for the domestic market.
Currently, macular degeneration treatment is an intravitreal injection type treatment, which is led by global pharmaceutical companies such as Novartis’ Lucentis® and Bayer’s Eylea®, and the market with a prescription of more than 100 billion won in 2021 (more than 20% CAGR over the past 3 years) is forming.
The macular degeneration treatment, which the two companies plan to jointly develop, is an eye drop form that can be treated only by eye drop administration if SCAI Therapeutics’ MOASIS™ technology is to be applied, without sticking a needle into the patient's eye as the existing intraocular injection form treatment.
MOASIS™ technology is a technology that improves bioavailability by increasing the cell penetration of drugs. Through this, it is possible to improve existing products, change the route of administration, expand the application to new conditions, and apply to the development of NCE (New Chemical Entity) that has not been commercialized.
Through active cooperation, the two companies plan to develop existing antibody injections into eye drops and introduce innovative products with improved patient compliance to the market.
Chul Hwan Kim, CEO of SCAI Therapeutics, expressed his determination, saying, “I am delighted to sign the first technology transfer contract with Daewoo Pharmaceutical, an ophthalmology company after the establishment of the corporation, and will prove the efficacy of MOASIS™ technology through clinical trials.”
Yong Hoon Ji, CEO of Daewoo Pharm, said, "Starting with securing Daewoo Pharm's new drug pipeline through SCAI Therapeutics' innovative drug delivery technology, we intend to conduct more active open innovation."
On the other hand, Daewoo Pharm is a prescription drug pharmaceutical company established in 1976. Since taking office in 2009 as CEO Yong Hoon Ji, a former Seoul National University Hospital ophthalmologist, Daewoo Pharm has been successfully transforming into a biopharmaceutical company specializing in ophthalmic drugs.
Recently, strategic investments of more than KRW 20 billion have been made to invest in ophthalmic drug facilities and expand new drug pipelines. It is establishing a strategy to grow into an ophthalmology specialty pharmaceutical company.
http://www.dailypharm.com/Users/News/NewsView.html?ID=288159&dpsearch=
Source: Daily Pharm (http://www.dailypharm.com/)
Through this contract, SCAI Therapeutics will transfer the technology of SCAI-003, which is being developed as an eye drop for macular degeneration treatment using the anticancer drug Sunitinib, to Daewoo Pharm, and Daewoo Pharm will grant joint clinical trials and exclusive sales rights for the domestic market.
Currently, macular degeneration treatment is an intravitreal injection type treatment, which is led by global pharmaceutical companies such as Novartis’ Lucentis® and Bayer’s Eylea®, and the market with a prescription of more than 100 billion won in 2021 (more than 20% CAGR over the past 3 years) is forming.
The macular degeneration treatment, which the two companies plan to jointly develop, is an eye drop form that can be treated only by eye drop administration if SCAI Therapeutics’ MOASIS™ technology is to be applied, without sticking a needle into the patient's eye as the existing intraocular injection form treatment.
MOASIS™ technology is a technology that improves bioavailability by increasing the cell penetration of drugs. Through this, it is possible to improve existing products, change the route of administration, expand the application to new conditions, and apply to the development of NCE (New Chemical Entity) that has not been commercialized.
Through active cooperation, the two companies plan to develop existing antibody injections into eye drops and introduce innovative products with improved patient compliance to the market.
Chul Hwan Kim, CEO of SCAI Therapeutics, expressed his determination, saying, “I am delighted to sign the first technology transfer contract with Daewoo Pharmaceutical, an ophthalmology company after the establishment of the corporation, and will prove the efficacy of MOASIS™ technology through clinical trials.”
Yong Hoon Ji, CEO of Daewoo Pharm, said, "Starting with securing Daewoo Pharm's new drug pipeline through SCAI Therapeutics' innovative drug delivery technology, we intend to conduct more active open innovation."
On the other hand, Daewoo Pharm is a prescription drug pharmaceutical company established in 1976. Since taking office in 2009 as CEO Yong Hoon Ji, a former Seoul National University Hospital ophthalmologist, Daewoo Pharm has been successfully transforming into a biopharmaceutical company specializing in ophthalmic drugs.
Recently, strategic investments of more than KRW 20 billion have been made to invest in ophthalmic drug facilities and expand new drug pipelines. It is establishing a strategy to grow into an ophthalmology specialty pharmaceutical company.
http://www.dailypharm.com/Users/News/NewsView.html?ID=288159&dpsearch=
Source: Daily Pharm (http://www.dailypharm.com/)